- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02434159
Role of Cardiac Computed Tomography in Optimising Response to Cardiac Resynchronisation Therapy
April 30, 2015 updated by: University College, London
Role of Cardiac Computed Tomography and Cardiac Magnetic Resonance in Optimising Response to Cardiac Resynchronisation Therapy
The purpose of this study is to determine if detailed scanning of the heart before biventricular device insertion will improve outcomes for heart failure patients.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom
- Recruiting
- University College London Hospital
-
Contact:
- Vanessa Cobb
- Email: nesscobb@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age > 18, <90
- Patients with moderate or severe heart failure ( NYHA functional class II-IV) due to ischaemic or non-ischaemic cardiomyopathy.
- QRS duration >120ms on 12 lead ECG
- LVEF < 35%
- LVEDD >55 mm
- Patients on optimum medical treatment for heart failure. The doses of these medications have been stable for 3 months.
Exclusion Criteria:
- Patients with a cardiac or cerebral ischemic event within the previous three months prior to recruitment
- Patients who had had an atrial arrhythmia within one month prior to recruitment
- Patients with a systolic blood pressure of more than 170 or less than 80 mm Hg
- Patients with a heart rate of more than 140 beats per minute
- Patients with severe renal failure (eGFR < 30)
- Patients with a history of allergy to iodine based contrast agents
- Predicted life expectancy < 1 year
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Scan
Heart scan prior to device insertion
|
|
|
No Intervention: No scan
No heart scan prior to device insertion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
6 minute walk test
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Anticipated)
September 1, 2017
Study Registration Dates
First Submitted
April 30, 2015
First Submitted That Met QC Criteria
April 30, 2015
First Posted (Estimate)
May 5, 2015
Study Record Updates
Last Update Posted (Estimate)
May 5, 2015
Last Update Submitted That Met QC Criteria
April 30, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11/0583
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.